SEARCH

SEARCH BY CITATION

References

  • 1
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
  • 2
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
  • 3
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
  • 4
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
  • 5
    Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
  • 6
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
  • 7
    Incivek prescribing information. May2011. Vertex Pharmaceuticals, Inc.,Cambridge, MA. 2011.
  • 8
    Victrelis prescribing information. May2011. Schering Corporation, a subsidiary of Merck and Co. Whitehouse Station, NJ.2011.
  • 9
    Hézode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). Oral presentation. International Liver Congress. 47th Annual Meeting of the European Association for the Study of the Liver, April 18-22, 2012, Barcelona, Spain.2012.
  • 10
    Ferenci P, Reddy KR. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antivir Ther 2011;16:1187-1201.
  • 11
    Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999;6:937-943.
  • 12
    Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003;278:49164-49170.
  • 13
    Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008;52:4356-4369.
  • 14
    Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006;17:79-87.
  • 15
    Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007;282:29812-29820.
  • 16
    Leveque V, Fung A, Le Pogam S, Kang H, Harris S, Cammack N, et al. Nucleoside analog R7128, a prodrug of PSI-6130, shows inhibition potency across HCV genotypes 1-6 in vitro. Poster P-215 presented at the 16th International Symposium on Hepatitis C Virus and Related Viruses, October 3-7,2009, Nice, France.
  • 17
    Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 2012;17:411-423.
  • 18
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-462.
  • 19
    Powdrill MH, Bernatchez JA, Gotte M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses 2010;2:2169-2195.
  • 20
    Reddy R, Rodriguez-Torres M, Gane E, Robson R, Lalezari J, Everson G, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy [abstract LB9]. Hepatology 2007;46( Suppl 4):862A.
  • 21
    Gane E, Rodriguez-Torres M, Nelson D, Jacobson I, McHutchison J, Jeffers L, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days [abstract LB10]. Hepatology 2008;48( Suppl 4):1024A.
  • 22
    Rodriguez-Torres M, Lalezari J, Gane E, DeJesus E, Nelson D, Everson G, et al. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with PEG-IFN and ribavirin: subanalysis by race/ethnicity, weight, and HCV genotype [abstract 1899]. Hepatology 2008;48( Suppl 4):1160A.
  • 23
    Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-1475.
  • 24
    Jensen D, Wedemeyer H, Herring R, Ferenci P, Ma H, Zeuzem S, et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: planned week 12 interim analysis from the PROPEL study. Oral presentation. The Liver Meeting 2010 [61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)], October 29-November 2,2010, Boston, MA.
  • 25
    Wedemeyer H, Jensen D, Herring R, Ferenci P, Ma MM, Zeuzem S, et al. PROPEL: a randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patientsHepatology 2013 Jan 14. doi: 10.1002/hep.26274.
  • 26
    Le Pogam S, Yan J-M, Kosaka A, Ji Y, Gonzaludo N, Ewing A, et al. No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and PEG-IFN/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study [abstract 799]. Hepatology 2010;52( Suppl 1):701A-702A.
  • 27
    Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, et al. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010;202:1510-1519.
  • 28
    Gane EJ, Pockros P, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/R with or without ribavirin in treatment-naive HCV genotype 1-infected patients [abstract 1412]. J Hepatol 2012;56( Suppl 2):S555-S556.
  • 29
    Feld JJ, Jacobson IR, Jensen DM, Foster G, Pol S, Tam E, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) + peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study [abstract 81]. Hepatology 2012;56( (Suppl 1):231A.